Ligand Pharmaceuticals | LGND - Ebitda


Ligand Pharmaceuticals reported $-14.3M in EBITDA for its fiscal quarter ending in March of 2026.





Ebitda Change Date
Agenus USD -10.11M 19.02M Mar/2025
Amgen USD 3.86B 1.28B Mar/2026
Anika Therapeutics USD 4.54M 3.67M Dec/2025
Arrowhead Research USD -107.35M 164.52M Mar/2026
Baxter International USD 309M 756M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Enviri Corporation USD 70.13M 4.29M Dec/2025
Gilead Sciences USD 3.51B 489M Mar/2026
GlaxoSmithKline GBP 3.51B 734M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -148.3M 165.88M Mar/2026
Intrexon USD -24.7M 2.92M Jun/2024
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
Karyopharm Therapeutics USD -26.2M 1.83M Sep/2024
Ligand Pharmaceuticals USD -14.3M 81.08M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Pacira USD 48.67M 8.43M Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Rigel Pharmaceuticals USD -4.17M 798K Sep/2023
Veracyte USD 43.96M 1.16M Jun/2026